501 Fifth Avenue
About EyenoviaEyenovia is a clinical stage, ophthalmic bio-pharmaceutical company which is transforming the way we treat eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia’s breakthrough piezo-dispersion and microdosing technology can enable a portfolio of next-generation, micro-therapeutics for the eye which are designed to significantly reduce ocular and systemic toxicity and greatly improve the risk-benefit profile of both new and existing treatments. At Eyenovia, we believe that when it comes to your eyes, smaller is better.
CEO & President: Sean Ianchulev, MD MPH
Chairman of the Board: Fred Eshelman, PhD
Director, Business Development and Finance: Curt Labelle, MD MBA
Please click here for Eyenovia's science.
Please click here for Eyenovia's pipeline.
17 articles with Eyenovia
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it has initiated its MicroPine Phase III program with the first patient enrolled in its CHAPERONE study.
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application to initiate the CHAPERONE study - the Company's Phase III registration trial of MicroPine to reduce the progression of myopia in children.
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from the MicroStat Phase 3 MIST-1 study.
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
Topline results for the Phase III MicroStat Program for pharmacologic mydriasis expected H1 2019
Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability
Eyenovia, Inc. (NASDAQ: EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-review journal Clinical Ophthalmology
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1
Topline results for Phase III MicroStat program expected H1 2019
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first of two Phase III trials (MIST-1 and MIST-2) of the Company’s MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam.
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eyenovia, Inc. (EYEN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eyenovia, Inc.
Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced positive results of its EYN PG21 proof-of-concept study of microdose latanoprost for the lowering of intraocular pressure (IOP) and patient usability.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services and Roth Capital Partners acted as joint book-running managers for the offering.
1/11/2018The company plans to offer 2.73 million shares priced between $10 and $12 each.
Eyenovia announced the appointment of John Gandolfo as Chief Financial Officer (CFO) effective December 18, 2017.
Eyenovia Publication of EYE 102 Phase II Results Demonstrates Strong Pharmacodynamic Effect, Tolerability and Reduced Systemic Exposure of High-Precision Micro-dosing compared to Conventional Eyedroppers
Eyenovia's micro-dose delivery of topical phenylephrine achieves comparable dilation results with a dose one-quarter the volume of a conventional pipette eye dropper.
Eyenovia Announces Publication Of Phase II Study Results Demonstrating Benefits Of Micro-Formulation Over Conventional Eyedroppers And Addition Of Scientific Advisory Board Members